RGEN - Repligen Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
61.76
+2.28 (+3.83%)
At close: 4:00PM EDT

61.10 -0.66 (-1.07%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close59.48
Open59.20
Bid49.07 x 900
Ask69.00 x 1100
Day's Range59.20 - 61.88
52 Week Range34.05 - 70.50
Volume557,398
Avg. Volume324,035
Market Cap2.713B
Beta (3Y Monthly)0.90
PE Ratio (TTM)166.92
EPS (TTM)0.37
Earnings DateMay 6, 2019 - May 10, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.00
Trade prices are not sourced from all markets
  • What Should Investors Know About Repligen Corporation’s (NASDAQ:RGEN) Future?
    Simply Wall St.9 days ago

    What Should Investors Know About Repligen Corporation’s (NASDAQ:RGEN) Future?

    The most recent earnings update Repligen Corporation's (NASDAQ:RGEN) released in December 2018 indicated that the company experienced a substantial headwind with earnings declining by -41%. Below, I've laid out keyRead More...

  • GuruFocus.com20 days ago

    Repligen Corp (RGEN) Files 10-K for the Fiscal Year Ended on December 31, 2018

    Repligen Corp is a bioprocessing company developing, producing and commercializing biologic drugs. Repligen Corp had annual average EBITDA growth of 1.80% over the past five years. Warning! GuruFocus has detected 4 Warning Signs with RGEN.

  • Thomson Reuters StreetEvents24 days ago

    Edited Transcript of RGEN earnings conference call or presentation 21-Feb-19 1:30pm GMT

    Q4 2018 Repligen Corp Earnings Call

  • Markit24 days ago

    See what the IHS Markit Score report has to say about Repligen Corp.

    Repligen Corp NASDAQ/NGS:RGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for RGEN with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on February 21. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding RGEN totaled $1.83 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Repligen Corp (RGEN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool28 days ago

    Repligen Corp (RGEN) Q4 2018 Earnings Conference Call Transcript

    RGEN earnings call for the period ending December 31, 2018.

  • Repligen (RGEN) Matches Q4 Earnings Estimates
    Zacks28 days ago

    Repligen (RGEN) Matches Q4 Earnings Estimates

    Repligen (RGEN) delivered earnings and revenue surprises of 0.00% and 3.20%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press28 days ago

    Repligen: 4Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had net income of 12 cents per share. Earnings, adjusted for one-time gains and costs, came to 21 cents per share. The results matched Wall Street expectations. ...

  • GlobeNewswire28 days ago

    Repligen Reports Fourth Quarter and Full Year 2018 Financial Results

    Record quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-year growthOverall organic.

  • GlobeNewswirelast month

    Repligen to Report Fourth Quarter and Full Year 2018 Financial Results

    WALTHAM, Mass., Feb. 15, 2019 -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2018 financial results on.

  • Is Repligen Corporation’s (NASDAQ:RGEN) Liquidity Good Enough?
    Simply Wall St.2 months ago

    Is Repligen Corporation’s (NASDAQ:RGEN) Liquidity Good Enough?

    Mid-caps stocks, like Repligen Corporation (NASDAQ:RGEN) with a market capitalization of US$2.4b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Read More...

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Incyte and Repligen

    NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. ...

  • Motley Fool2 months ago

    3 Pick-and-Shovel Biotechnology Stocks

    These biotech suppliers have performed extremely well for investors. Here's why each of them is poised for prosperity.

  • Motley Fool2 months ago

    How to Play It Safe in Biotech

    Risk-averse investors might be surprised how safe some of these companies are in one of the most volatile sectors on the market.

  • GlobeNewswire2 months ago

    Consolidated Research: 2019 Summary Expectations for Post, Westlake Chemical, Repligen, Weingarten Realty Investors, AptarGroup, and At Home Group — Fundamental Analysis, Key Performance Indications

    NEW YORK, Jan. 23, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • MoneyShow2 months ago

    Top Picks 2019- Repligen RGEN

    Repligen (RGEN) is a pure-play supplier of bioprocessing technologies. It is a market leader in proteins (over 95% market share), where it has a near monopoly, explains Tyler Laundon, editor of Cabot Small-Cap Confidential.

  • GlobeNewswire3 months ago

    Repligen to Present at 37th Annual J.P. Morgan Healthcare Conference

    WALTHAM, Mass., Jan. 03, 2019 -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will.

  • Is Repligen Corporation (RGEN) A Good Stock To Buy?
    Insider Monkey3 months ago

    Is Repligen Corporation (RGEN) A Good Stock To Buy?

    Hedge fund managers like David Einhorn, Dan Loeb, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • Have Insiders Been Selling Repligen Corporation (NASDAQ:RGEN) Shares This Year?
    Simply Wall St.3 months ago

    Have Insiders Been Selling Repligen Corporation (NASDAQ:RGEN) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...

  • ANIK vs. RGEN: Which Stock Should Value Investors Buy Now?
    Zacks3 months ago

    ANIK vs. RGEN: Which Stock Should Value Investors Buy Now?

    ANIK vs. RGEN: Which Stock Is the Better Value Option?